Anti-cytokine therapeutics and infections - PubMed (original) (raw)
Review
Anti-cytokine therapeutics and infections
Charles A Dinarello. Vaccine. 2003.
Abstract
In view of the increasing use of anti-cytokine-based therapies to treat autoimmune diseases, the role of specific cytokines in host defense against infection has become a highly relevant area of investigation. There are over 300,000 patients worldwide being treated with agents that specifically block the biological activities of interleukin-1 (IL-1) or tumor necrosis factor (TNF) for reducing the severity of autoimmune diseases such as rheumatoid arthritis, Crohn's disease or psoriasis. Those patients receiving anti-TNF-alpha or IL-1 blocking therapies are treated on a chronic basis. Studies suggest that other chronic inflammatory diseases will benefit from anti-cytokine therapies. However, there is a growing body of clinical evidence that neutralization of TNF-alpha is associated with an increased risk of opportunistic infections, including mycobacterial diseases. Blockade of IL-1 activity with the IL-1 receptor antagonist (IL-1Ra) appears, at present, to be relatively safe. However, because of physician under reporting (some estimates of reporting being less than 5% of these infections), the true incidence of infections, both serious and non-serious, will remain unknown. Does the increase in infections associated with anti-cytokine-based therapies come as a surprise? Of the two components of host defense, the innate and the acquired responses, which are affected by anti-cytokine therapies? From a wealth of rodent studies using live infection models, the following conclusions can be drawn: (1) neutralization or gene deletion for TNF-alpha is frequently associated with reduction of host defense in models of live Gram-positive or Gram-negative infections as well as infection by intracellular microbes such as Salmonella and Listeria; (2) absence of the IL-1 receptor can also result in decreased resistance to Listeria or Gram-positive bacteria and (3) TNF-alpha and IFN-gamma are required for defense against infection caused by Mycobacterium tuberculosis.
Similar articles
- [Tuberculosis in compromised hosts].
[No authors listed] [No authors listed] Kekkaku. 2003 Nov;78(11):717-22. Kekkaku. 2003. PMID: 14672050 Japanese. - Lipopolysaccharide-induced cytokine production and mortality in mice treated with Corynebacterium parvum.
Smith SR, Calzetta A, Bankowski J, Kenworthy-Bott L, Terminelli C. Smith SR, et al. J Leukoc Biol. 1993 Jul;54(1):23-9. doi: 10.1002/jlb.54.1.23. J Leukoc Biol. 1993. PMID: 8336076 - Cytokine mediators of septic infections in the normal and granulocytopenic host.
Waage A, Steinshamn S. Waage A, et al. Eur J Haematol. 1993 May;50(5):243-9. doi: 10.1111/j.1600-0609.1993.tb00156.x. Eur J Haematol. 1993. PMID: 8319784 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
- Identification of fever and vaccine-associated gene interaction networks using ontology-based literature mining.
Hur J, Ozgür A, Xiang Z, He Y. Hur J, et al. J Biomed Semantics. 2012 Dec 20;3(1):18. doi: 10.1186/2041-1480-3-18. J Biomed Semantics. 2012. PMID: 23256563 Free PMC article. - Autoimmunity as a predisposition for infectious diseases.
Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri S, Bayry J. Maddur MS, et al. PLoS Pathog. 2010 Nov 4;6(11):e1001077. doi: 10.1371/journal.ppat.1001077. PLoS Pathog. 2010. PMID: 21079687 Free PMC article. No abstract available. - Vitamin D, Its Role in Recovery after Muscular Damage Following Exercise.
Caballero-García A, Córdova-Martínez A, Vicente-Salar N, Roche E, Pérez-Valdecantos D. Caballero-García A, et al. Nutrients. 2021 Jul 8;13(7):2336. doi: 10.3390/nu13072336. Nutrients. 2021. PMID: 34371846 Free PMC article. Review. - Identification of Lactobacillus strains with probiotic features from the bottlenose dolphin (Tursiops truncatus).
Diaz MA, Bik EM, Carlin KP, Venn-Watson SK, Jensen ED, Jones SE, Gaston EP, Relman DA, Versalovic J. Diaz MA, et al. J Appl Microbiol. 2013 Oct;115(4):1037-51. doi: 10.1111/jam.12305. Epub 2013 Aug 1. J Appl Microbiol. 2013. PMID: 23855505 Free PMC article. - IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice.
Ali A, Na M, Svensson MN, Magnusson M, Welin A, Schwarze JC, Mohammad M, Josefsson E, Pullerits R, Jin T. Ali A, et al. PLoS One. 2015 Jul 2;10(7):e0131645. doi: 10.1371/journal.pone.0131645. eCollection 2015. PLoS One. 2015. PMID: 26135738 Free PMC article.